Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences

Rhea-AI Summary

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology firm, announced its participation in seven investor conferences throughout April to June 2022. Key events include the Canaccord Genuity Horizons in Oncology Virtual Conference on April 14, BofA Securities Healthcare Conference on May 10, and the Stifel Virtual Cell Therapy Conference on June 30. Webcasts for these events will be available on their website, with replays accessible for 30 days. Allogene focuses on developing allogeneic CAR T products aiming to provide effective cancer treatments to patients.

SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to participate in seven upcoming investor conferences.

Canaccord Genuity Horizons in Oncology Virtual Conference
Thursday, April 14, 2022
8:00AM PT/11:00AM ET

BofA Securities 2022 Healthcare Conference
Tuesday, May 10, 2022
8:00AM PT/11:00AM ET 

2022 RBC Capital Markets Global Healthcare Conference
Tuesday, May 17, 2022
8:30AM PT/11:30AM ET

Jefferies Global Healthcare Conference
Wednesday, June 8-Thursday, June 9, 2022
Details to be posted to the Company’s website

Goldman Sachs 43rd Annual Global Healthcare Conference
Monday, June 13, 2022
Details to be posted to the Company’s website

2022 Truist Securities Cell Therapy Symposium
Tuesday, June 28, 2022
Details to be posted to the Company’s website

Stifel Virtual Cell Therapy Conference
Thursday, June 30, 2022
8:30AM PT/11:30AM ET

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live webcast, a replay will be available on the Company's website for approximately 30 days.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T products for cancer and the potential benefits of AlloCAR T. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-K for the year ended December 31, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com

FAQ

What upcoming investor conferences will Allogene Therapeutics participate in?

Allogene Therapeutics will participate in seven investor conferences from April to June 2022, including the Canaccord Genuity Horizons in Oncology Virtual Conference and the BofA Securities Healthcare Conference.

When is the Canaccord Genuity Horizons in Oncology Virtual Conference?

The Canaccord Genuity Horizons in Oncology Virtual Conference is scheduled for April 14, 2022, at 8:00 AM PT.

What is the focus of Allogene Therapeutics as a biotechnology company?

Allogene Therapeutics is focused on developing allogeneic CAR T (AlloCAR T™) products aimed at treating cancer.

How can I access the webcasts from Allogene's investor conferences?

Webcasts from Allogene's investor conferences will be posted on their website under the Investors tab in the News and Events section.

What is the goal of Allogene’s CAR T cell therapy products?

The goal of Allogene's CAR T cell therapy products is to provide readily available, off-the-shelf cancer treatments that are more reliable and scalable for patients.